TNFRSF17 and plasma cell myeloma: Anti-BCMA CAR T cells therapies have been FDA-approved for refractory multiple myeloma, thus, increasing the number of clinical trials for anti-BCMA CAR T cell therapies being applied in other applications (49, 50).